Maintenance therapy options for ulcerative colitis

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 10, 2016, Pages 1339-1349

  Chaparro, María ^a   Gisbert, Javier P ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

adalimumab; azathioprine; biosimilar; golimumab and vedolizumab; infliximab; mercaptopurine; mesalamine; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOSIMILAR AGENT; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SALICYLIC ACID DERIVATIVE; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ALLERGY; ANTIPROLIFERATIVE ACTIVITY; ARTHRALGIA; BACTERIAL INFECTION; BONE MARROW TOXICITY; DELAYED HYPERSENSITIVITY; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; FEVER; FLATULENCE; HAND INFECTION; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; INFECTION; INJECTION SITE PAIN; INTERSTITIAL NEPHRITIS; LIVER TOXICITY; MAINTENANCE THERAPY; MALAISE; MYALGIA; NAUSEA; OPPORTUNISTIC INFECTION; PANCREATITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REMISSION; REVIEW; RHINOPHARYNGITIS; TREATMENT INDICATION; ULCERATIVE COLITIS; VIRUS INFECTION; WEAKNESS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; HUMANS; IMMUNOLOGIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84975259862     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1187132     Document Type: Review

References (84)

1. A.Dignass, R.Eliakim, F.Magro, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012 Dec;6(10):965–990.•• Recommendations from the European Crohn’s and Colitis Organisation.
2. T.Oresland, W.A.Bemelman, G.M.Sampietro, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 2015 Jan;9(1):4–25.•• Recommendations from the European Crohn’s and Colitis Organisation.
3. A.Dignass, J.O.Lindsay, A.Sturm, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012 Dec;6(10):991–1030.•• Recommendations from the European Crohn’s and Colitis Organisation.
4. E.Langholz, P.Munkholm, M.Davidsen, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994 Jul;107(1):3–11.
5. I.C.Solberg, I.Lygren, J.Jahnsen, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–440.•• Recommendations from the European Crohn’s and Colitis Organisation.
6. J.K.Marshall, M.Thabane, A.H.Steinhart, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.• Systematic review on the efficacy of salycilates in UC.
7. W.J.Sandborn, S.B.Hanauer Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan;17(1):29–42.
8. L.Sutherland, J.K.Macdonald. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.• Systematic review on the efficacy of salycilates in UC.
9. B.G.Feagan, J.K.Macdonald. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543.• Systematic review on the efficacy of salycilates in UC.
10. M.A.Kamm, W.J.Sandborn, M.Gassull, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan;132(1):66–75;quiz 432–433.
11. W.Kruis, G.Kiudelis, I.Racz, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009 Feb;58(2):233–240.•• Clinical trial that demonstrated that once-daily dosage of mesalamine is as effective as split dosage.
12. L.Leifeld, R.Pfutzer, J.Morgenstern, et al. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis. Aliment Pharmacol Ther. 2011 Nov;34(9):1115–1122.
13. C.S.Probert, A.U.Dignass, S.Lindgren, et al. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 2014 Mar;8(3):200–207.
14. P.Marteau, C.S.Probert, S.Lindgren, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005 Jul;54(7):960–965.
15. M.Safdi, M.DeMicco, C.Sninsky, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997 Oct;92(10):1867–1871.• Randomized clinical trial that demonstrated that combined oral and rectal treatment is more effective than oral therapy alone.
16. M.J.Shale, S.A.Riley. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Jul 15;18(2):191–198.
17. A.Lopez San Roman, F.Bermejo, E.Carrera, et al. Adherence to treatment in inflammatory bowel disease. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva. 2005 Apr;97(4):249–257.
18. O.A.Paoluzi, F.Iacopini, R.Pica, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther. 2005 May 1;21(9):1111–1119.
19. S.B.Hanauer. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct;24(Suppl 3):37–40.
20. J.P.Gisbert, Y.Gonzalez-Lama, J.Mate. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007 May;13(5):629–638.
21. A.Kornbluth, D.B.Sachar. Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar;105(3):501–523;quiz 24.
22. J.P.Gisbert, F.Gomollon, J.Mate, et al. [Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity]. Rev Clin Esp. 2002 Oct;202(10):555–562.
23. S.K.Yang, M.Hong, J.Baek, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014 Sep;46(9):1017–1020.
24. W.Zabala, R.Cruz, M.Barreiro-de Acosta, et al. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. Pharmacogenomics. 2013 Apr;14(6):631–640.
25. C.A.Siegel, B.E.Sands. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005 Jul 1;22(1):1–16.
26. J.P.Gisbert, P.M.Linares, A.G.McNicholl, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009 Jul 1;30(2):126–137.•• Meta-analysis on the efficacy of thiopurines in UC.
27. M.T.Osterman, R.Kundu, G.R.Lichtenstein, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006 Apr;130(4):1047–1053.
28. M.C.Dubinsky, E.Reyes, J.Ofman, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005 Oct;100(10):2239–2247.
29. P.W.Lowry, C.L.Franklin, A.L.Weaver, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001 Nov;49(5):665–670.
30. L.O.Reuther, J.Sonne, N.E.Larsen, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol. 2003 Sep;38(9):972–977.
31. Y.Gonzalez-Lama, F.Bermejo, A.Lopez-Sanroman, et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther. 2011;34(5):544–554.• Study that demonstrate that zathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
32. E.Prefontaine, L.R.Sutherland, J.K.Macdonald, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD000067.
33. M.Chaparro, I.Ordas, E.Cabre, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013 Jun;19(7):1404–1410.
34. J.P.Gisbert, F.Gomollon. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008 Jul;103(7):1783–1800.
35. J.P.Gisbert, Y.Gonzalez-Lama, J.Mate. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007 Jul;102(7):1518–1527.
36. A.Kandiel, A.G.Fraser, B.I.Korelitz, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–1125.•• Study that suggested that there was an increased risk of lymphoma in IBD patients treated with thiopurines.
37. L.Beaugerie, N.Brousse, A.M.Bouvier, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009 Nov 7;374(9701):1617–1625.•• Study that suggested that there was an increased risk of lymphoma in IBD patients treated with thiopurines.
38. D.S.Kotlyar, J.D.Lewis, L.Beaugerie, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847–850;quiz e48–50.
39. D.S.Kotlyar, W.Blonski, R.H.Diamond, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol. 2010 Oct;105(10):2299–2301.
40. J.Ariyaratnam, V.Subramanian. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014 Feb;109(2):163–169.
41. F.Atzeni, M.Turiel, F.Capsoni, et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005;1051:559–569.
42. P.Rutgeerts, W.J.Sandborn, B.G.Feagan, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476.
43. W.J.Sandborn, P.Rutgeerts, B.G.Feagan, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–1260;quiz 520.•• Post-hoc analysis of the ACT-1 and 2 trials assessing the impact of infliximab on the need of colectomy in UC patients.
44. D.Laharie, A.Bourreille, J.Branche, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012 Dec 1;380(9857):1909–1915.
45. M.Chaparro, P.Burgueno, E.Iglesias, et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther. 2012 Jan;35(2):275–283.
46. M.Manosa, A.Lopez San Roman, E.Garcia-Planella, et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion. 2009;80(1):30–35.
47. K.B.Gecse, B.D.Lovasz, K.Farkas, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016 Feb;10(2):133–140.
48. J.Jahnsen, T.E.Detlie, S.Vatn, et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):45–52.
49. S.H.Park, Y.H.Kim, J.H.Lee, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44.
50. S.B.Hanauer, B.G.Feagan, G.R.Lichtenstein, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549.
51. B.E.Sands, F.H.Anderson, C.N.Bernstein, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004 Feb 26;350(9):876–885.
52. R.Panaccione, S.Ghosh, S.Middleton, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 Feb;146(2):392–400e3.• Study that demonstrated that combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in UC.
53. J.P.Gisbert, J.Panes. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009 Mar;104(3):760–767.
54. M.Chaparro, I.Guerra, P.Munoz-Linares, et al. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012 May;35(9):971–986.
55. S.Ben-Horin, M.Yavzori, L.Katz, et al. The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011 Jan;60(1):41–48.
56. A.C.Ford, W.J.Sandborn, K.J.Khan, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–659;quiz 60.
57. F.Wolfe, K.Michaud. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004 Jun;50(6):1740–1751.
58. L.Biancone, S.Zuzzi, M.Ranieri, et al. Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012 Jun;6(5):578–587.
59. U.Kopylov, M.Vutcovici, A.Kezouh, et al. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a quebec claims database study. Inflamm Bowel Dis. 2015 Aug;21(8):1847–1853.
60. W.Reinisch, W.J.Sandborn, D.W.Hommes, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780–787.
61. W.J.Sandborn, G.van Assche, W.Reinisch, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257–265e1–3.
62. J.F.Colombel, W.J.Sandborn, S.Ghosh, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov;109(11):1771–1780.
63. S.B.Hanauer, W.J.Sandborn, P.Rutgeerts, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb;130(2):323–333;quiz 591.
64. B.G.Feagan, W.J.Sandborn, A.Lazar, et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan;146(1):110–18e3.
65. A.Oussalah, C.Laclotte, J.B.Chevaux, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008 Oct 15;28(8):966–972.
66. W.Afif, J.A.Leighton, S.B.Hanauer, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep;15(9):1302–1307.
67. N.Gies, K.I.Kroeker, K.Wong, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010 Aug;32(4):522–528.
68. C.Taxonera, J.Estelles, I.Fernandez-Blanco, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011 Feb;33(3):340–348.
69. E.McDermott, S.Murphy, D.Keegan, et al. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis. 2013 Mar;7(2):150–153.
70. O.Garcia-Bosch, J.P.Gisbert, A.Canas-Ventura, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013 Oct;7(9):717–722.
71. Italian Group for the Study of Inflammatory, D.Bowel, A.Armuzzi, L.Biancone, et al. Adalimumab in active ulcerative colitis: a “real-life” observational study. Dig Liver Dis. 2013 Sep;45(9):738–743.
72. G.Hutas. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther. 2008 Aug;10(4):393–406.
73. N.Lonberg. Human antibodies from transgenic animals. Nat Biotechnol. 2005 Sep;23(9):1117–1125.
74. D.J.Shealy, A.Cai, K.Staquet, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. mAbs. 2010 Jul-Aug;2(4):428–439.
75. W.J.Sandborn, B.G.Feagan, C.Marano, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):85–95;quiz e14–e15.
76. W.J.Sandborn, B.G.Feagan, C.Marano, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109e1.
77. J.K.Marshall. LDP-02 (Millenium). Curr Opin Invest Drugs. 2001 Apr;2(4):502–504.
78. Y.Tsuzuki, S.Miura, M.Suematsu, et al. Alpha 4 integrin plays a critical role in early stages of T lymphocyte migration in Peyer’s patches of rats. Int Immunol. 1996 Mar;8(3):287–295.
79. H.Tilg, A.Kaser. Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn’s disease. Curr Opin Invest Drugs. 2010 Nov;11(11):1295–1304.
80. H.S.Souza, C.C.Elia, J.Spencer, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999 Dec;45(6):856–863.
81. B.G.Feagan, P.Rutgeerts, B.E.Sands, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.•• Randomized clinical trial on the efficacy of vedolizumab in UC.
82. H.Hanauer, P.Rutgeerts, J.Xu, et al. Long-term efficacy of vedolizumab therapy for Crohn’s disease. United Eur Gastroenterol J. 2014;2014(2):A66.
83. W.J.Sandborn, B.G.Feagan, P.Rutgeerts, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013 Aug 22;369(8):711–721.
84. B.E.Sands, B.G.Feagan, P.Rutgeerts, et al. Vedolizumab induction therapy for patients with Crohn’s disease and prior anti-tumour necrosis factor antagonist failure: a randomised placebo-controlled, double-blind, multicenter trial. J Crohns Colitis. 2013;7(Suppl. 1):S5–S6.